These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 8835112)

  • 21. A phase I/II trial of zidovudine, interferon-alpha, and granulocyte-macrophage colony-stimulating factor in the treatment of human immunodeficiency virus type 1 infection.
    Davey RT; Davey VJ; Metcalf JA; Zurlo JJ; Kovacs JA; Falloon J; Polis MA; Zunich KM; Masur H; Lane HC
    J Infect Dis; 1991 Jul; 164(1):43-52. PubMed ID: 1676045
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Zidovudine twice daily in asymptomatic subjects with HIV infection and a high risk of progression to AIDS: a randomized, double-blind placebo-controlled study. The European-Australian Collaborative Group (Study 017).
    Mulder JW; Cooper DA; Mathiesen L; Sandström E; Clumeck N; Gatell JM; French M; Donovan B; Gray F; Yeo JM
    AIDS; 1994 Mar; 8(3):313-21. PubMed ID: 7913326
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. The European-Australian Collaborative Group.
    Cooper DA; Gatell JM; Kroon S; Clumeck N; Millard J; Goebel FD; Bruun JN; Stingl G; Melville RL; González-Lahoz J
    N Engl J Med; 1993 Jul; 329(5):297-303. PubMed ID: 8100611
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Do HIV type 1 RNA levels provide additional prognostic value to CD4(+) T lymphocyte counts in patients with advanced HIV type 1 infection?
    Arduino JM; Fischl MA; Stanley K; Collier AC; Spiegelman D
    AIDS Res Hum Retroviruses; 2001 Aug; 17(12):1099-105. PubMed ID: 11522179
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The predictive value of changes in serologic and cell markers of HIV activity for subsequent clinical outcome in patients with asymptomatic HIV disease treated with zidovudine.
    Jacobson MA; De Gruttola V; Reddy M; Arduino JM; Strickland S; Reichman RC; Bartlett JA; Phair JP; Hirsch MS; Collier AC
    AIDS; 1995 Jul; 9(7):727-34. PubMed ID: 7546418
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Toxic effects of zidovudine in asymptomatic human immunodeficiency virus-infected individuals with CD4+ cell counts of 0.50 x 10(9)/L or less. Detailed and updated results from protocol 019 of the AIDS Clinical Trials Group.
    Koch MA; Volberding PA; Lagakos SW; Booth DK; Pettinelli C; Myers MW
    Arch Intern Med; 1992 Nov; 152(11):2286-92. PubMed ID: 1359846
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunologic markers of AIDS progression: consistency across five HIV-infected cohorts. Multicohort Analysis Project Workshop. Part I.
    AIDS; 1994 Jul; 8(7):911-21. PubMed ID: 7946100
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The efficacy of combined zidovudine and lamivudine compared with that of combined zidovudine, lamivudine and nelfinavir in asymptomatic and early symptomatic HIV-infected children.
    Moolasart P; Likanonsakul S
    Southeast Asian J Trop Med Public Health; 2002 Jun; 33(2):280-7. PubMed ID: 12236426
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Virologic and CD4 cell response to zidovudine or zidovudine and lamivudine following didanosine treatment of human immunodeficiency virus infection.
    Katzenstein DA; Hughes MD; Albrecht M; Liou SH; Murphy R; Balfour H; Para M; Hammer S;
    AIDS Res Hum Retroviruses; 2001 Feb; 17(3):203-10. PubMed ID: 11177402
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus.
    Cheeseman SH; Havlir D; McLaughlin MM; Greenough TC; Sullivan JL; Hall D; Hattox SE; Spector SA; Stein DS; Myers M
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Feb; 8(2):141-51. PubMed ID: 7530585
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Growth factors and HIV-infection in children.
    Zuccotti GV; Flumine P; Locatelli V; Banderali G; Riva E
    J Int Med Res; 1993; 21(6):342-5. PubMed ID: 7511543
    [TBL] [Abstract][Full Text] [Related]  

  • 32. AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients.
    AIDS; 2000 Mar; 14(4):367-74. PubMed ID: 10770538
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The use of hematopoietic growth factors in HIV infection and AIDS-related malignancies.
    Miles SA
    Cancer Invest; 1991; 9(2):229-38. PubMed ID: 1713806
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rapid plasma virus and CD4+ T-cell turnover in HIV-1 infection: evidence for an only transient interruption by treatment.
    Stellbrink HJ; Zöller B; Fenner T; Lichtenberg G; van Lunzen J; Albrecht H; Thiele HG; Greten H
    AIDS; 1996 Jul; 10(8):849-57. PubMed ID: 8828742
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. AIDS Clinical Trials Group (ACTG) Study 152 Team.
    Englund JA; Baker CJ; Raskino C; McKinney RE; Petrie B; Fowler MG; Pearson D; Gershon A; McSherry GD; Abrams EJ; Schliozberg J; Sullivan JL
    N Engl J Med; 1997 Jun; 336(24):1704-12. PubMed ID: 9182213
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and activity of zalcitabine and zidovudine combination in HIV-positive people with CD4 cell counts < or = 300 cells/mm3. The Roche M50002 Study Group.
    Moyle GJ; Walker M; Harris R; Kellagher A; Warburg M
    Antivir Ther; 1996 Aug; 1(3):180-8. PubMed ID: 11322252
    [TBL] [Abstract][Full Text] [Related]  

  • 37. AVANTI 1: randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus loviride in HIV-infected antiretroviral-naive patients. AVANTI Study Group.
    Gatell J; Lange J; Gartland M
    Antivir Ther; 1999; 4(2):79-86. PubMed ID: 10682152
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial.
    Lancet; 1997 May; 349(9063):1413-21. PubMed ID: 9164314
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Behaviour of different clinical, immunological and serological parameters observed in a group of HIV positive patients during a 12 month treatment period with zidovudine.
    Crocchiolo PR; Lizioli A; Arcidiacono I; Cantaluppi P; Filippi C; Sobatti D; Bedarida G; D'Agostino F; Cambie G; Nardella ML
    Boll Ist Sieroter Milan; 1990 Jun; 69(2):423-30. PubMed ID: 1983798
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized double-blind trial of the addition of lamivudine or matching placebo to current nucleoside analogue reverse transcriptase inhibitor therapy in HIV-infected children: the PENTA-4 trial. Paediatric European Network for Treatment of AIDS.
    AIDS; 1998 Oct; 12(14):F151-60. PubMed ID: 9792371
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.